Hormones regulate nearly every major system in the body: metabolism, mood, fertility, sleep, cognition, cardiovascular function, and immune response. Their effects are deeply interconnected and highly individual. Hormones function as the operating system of the body, and when that system runs without monitoring, the result is delayed answers and an incomplete picture of what is actually happening.
Today, most women navigate hormonal changes without that picture. Fatigue, weight fluctuation, irregular cycles, infertility, perimenopausal symptoms, and mood instability are typically evaluated through single-point lab tests, interpreted through population reference ranges, and addressed through care models that rarely account for where a woman is in her life or her cycle. Women also spend 25% more of their lives in poor health than men, and the combined U.S. economic burden of endometriosis, autoimmune disease, and menopause-related productivity loss is estimated at well above $200 billion annually. Globally, closing the women's health gap could add $1 trillion to GDP by 2040.
The Femtech Horizon Map for Hormone Health surfaces a growing set of companies building across the continuum of care, ranging from at-home testing and wearables to clinician-supported care delivery, interpretation platforms, and next-generation biosensors. What emerges is the early outline of a new industry, one that treats hormone health as a longitudinal system that can be measured, tracked, and acted on across reproductive years, perimenopause, menopause, and aging.
For this report, we included companies and research groups working on female sex hormones (estrogen, progesterone, LH, FSH), thyroid hormones, and cortisol, along with care delivery and interpretation tools that help women and clinicians make sense of hormone data.
Hormone health overlaps with several of our other Femtech Horizon Maps, including fertility, peri/menopause, menstrual health, and uterine health. Here we focus on the companies positioned most specifically around hormone measurement, management, and the emerging category of continuous hormone monitoring.
The current landscape becomes clearer when viewed through how hormone measurement has developed over time.
For decades, hormone data was limited to single-point blood draws conducted in clinical settings. These tests, supported by infrastructure from Abbott Diagnostics, Roche Diagnostics, and Siemens Healthineers, remain the clinical standard for accuracy, and provide a narrow view into a highly dynamic system. Roche's cobas Mass Spec solution, which received the 2024 Best New Clinical Diagnostics Instrumentation award in the Scientists' Choice Awards, is the current gold standard for steroid hormone measurement in endocrinology labs.
At-home collection kits expanded access through the 2010s. Platforms such as Everlywell, LetsGetChecked, Ro (Modern Fertility), Hertility Health, Joi + Blokes, Marek Diagnostics, and Rupa Health made testing accessible across fertility, thyroid, and menopause-related panels. Results were still delivered through centralized labs, and the entry point moved into the home. Precision Analytical's DUTCH Test sits in a related category, using dried urine sampling across a 24-hour window to capture hormone metabolites.
More recently, at-home testing has moved closer to real-time use. Daily or near-daily urine and saliva testing lets individuals observe hormone patterns across a cycle, building a fuller view than single readings can provide. Proov, Oova, Inito, Mira, Hormona, Inne, Eli Health, Ovul, and QanikDX have defined this category, with several (including Proov, Inne, and Hertility) already cleared by regulatory bodies. These tools have been especially useful for fertility timing and early perimenopause awareness.
A parallel wave is entering through wearables. Oura, Clair, Ava, and related multi-biomarker platforms capture physiological signals such as skin temperature, heart rate variability, and sleep architecture, and use these inputs to estimate hormonal states and cycle phases. Natural Cycles, the first FDA-cleared Class II medical device app for contraception, established that this category can meet a regulatory bar.
A separate set of companies and research groups is working toward direct hormone sensing, aiming to measure hormones in the body continuously. Impli, BioSens8, Monix Health, Kiffik, Adaptyx, Level Zero Health, Persperity Health, Lume Health, EnLiSense, Nutrix AG, Unravel Health, and Vivoo are working in this area, alongside academic groups including CalTech's Gao Research Group and Johns Hopkins' CortiTrack team. Their approaches range from subcutaneous implants and interstitial fluid sensors to sweat-based and saliva-based biosensors and biosensor-enabled menstrual products.
A critical distinction (often blurred in product marketing) is the difference between inferring hormonal states from proxy signals and measuring hormones directly. In a recent analysis of the continuous hormone monitoring category, Alex Araki, who has been helping to scope a new ARPA-style program in this space, outlines three fundamentally different categories of technology being grouped under the same umbrella:
Each category involves trade-offs between accuracy, cost, convenience, and durability. Problems arise when companies blur the lines, for instance when a wrist-worn device claims continuous estrogen, progesterone, LH, and FSH tracking without disclosing a sensing mechanism for actual hormone detection. Cycle-phase classification from proxy signals is valuable on its own terms. Describing it as continuous hormone monitoring risks eroding trust in a field where women have already been dismissed for decades.
Marketing claims in this space outpace the clinical reality. On the map, we have marked tools that infer hormonal states from proxy signals (such as temperature and heart rate variability) with an asterisk, so readers can see this distinction at a glance.
A few patterns are evident across the companies and research we reviewed.
Hormone data is being treated as longitudinal. Across fertility, perimenopause, and menopause, the growing consensus is that meaningful interpretation depends on pattern data over time, captured across multiple points in a cycle or life stage.
Testing is moving closer to the individual. What was once confined to centralized labs now runs through at-home kits, daily testing products, and a growing pipeline of sensor-based platforms designed to reduce friction and increase frequency.
Hormone health is expanding beyond fertility. Fertility remains a primary entry point, and companies such as Allara Health, Tia Health, Coven Women's Health, and Solence are positioning hormone care within broader frameworks that include PCOS, metabolic dysfunction, perimenopause, and long-term health management.
Longevity platforms are incorporating hormones as core biomarkers. Function Health, InsideTracker, Lifeforce, Superpower, Mito Health, Nia Health, and SiPhox Health now include hormone panels in broader longevity and biomarker offerings, treating hormones as part of whole-body health relevant across metabolic, cardiovascular, and cognitive systems.
The interpretation layer is becoming its own category. As more tools enter the market, the ability to translate complex data into clinically meaningful insight is emerging as a distinct innovation front. Dama Health has built an AI co-pilot for hormone health that combines frontier models with clinical guidelines, society statements, and expert consensus guides developed with hormone specialists, aiming to make specialist-level frameworks available at the point of care. Forth's HealthCoach plays a related role on the consumer side, translating biomarker results into tailored recommendations.
Several signals point to growing scientific and commercial interest in this space.
Hormone health is moving toward a model defined by continuous data and longitudinal understanding. The next phase is likely to include clinically validated continuous monitoring systems, deeper integration of hormone data into clinical workflows, and more precise individualized treatment across fertility, perimenopause, menopause, and long-term health.
Expansion into employer-sponsored benefits and payer-supported care is also likely, particularly as hormone health becomes more clearly linked to productivity, chronic disease prevention, and healthspan outcomes. The McKinsey Health Institute has placed the global productivity cost of the women's health gap at approximately $1 trillion annually.
In the near term, commercial activity and opportunity for builders will concentrate across several areas:
Further out, continuous hormone monitoring, if developed with the technical rigor and foundational data infrastructure it requires, will open a new category of consumer and clinical products. CGMs took more than twenty years from first concept to the devices we know today. CHMs will likely require at least five to ten years more of sustained, well-funded R&D to reach similar maturity.
The caution, as Araki and others have pointed out, is that hype outrunning the science will damage trust with women who have already been dismissed by healthcare for decades. Building responsibly means being specific about what a product actually measures, validating across diverse populations, and treating privacy and data governance as first-class concerns.
The Femtech Horizon Map for Hormone Health reflects a category in the early stages of defining a new model of care. The movement from single data points to continuous data, from episodic testing to ongoing monitoring, and from reactive intervention to earlier understanding is becoming visible across the landscape. Standards are still being set. Clinical pathways are still being built. The direction of travel is consistent. Hormone health is becoming measurable over time, and the companies building in this space are defining how that measurement will be used.
Femovate is a women-owned, women-led company specializing in product strategy, design, and validation for women's health solutions. If you are building in hormone health, whether in sensors, testing platforms, care delivery, or interpretation, our team can help bring your innovation to market. Reach out through LinkedIn or our website to collaborate.
Our Femtech Horizon Maps highlight technologies across women's health, showing where innovation is emerging and where gaps remain. By visualizing the full continuum of care for specific verticals, these maps help founders, clinicians, and investors identify opportunities and build more integrated solutions. This is one of twenty maps in our series spanning women's health verticals.
These sources are referenced directly in the report or offer deeper perspectives on continuous hormone monitoring, femtech infrastructure, and the business case for women's health investment.
Thank you to Katrina Gaedcke for pulling the companies together, Mario Sierra, CCRC for sharing your research, Alex S. Araki for the great framing.
Fueling femtech innovation with design capital and strategic support for early-stage women’s health startups
